AASLD Briefs: Merck HCV Combo’s Four- and Six-Week Data Disappoint, Upside Seen For Gilead
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s proprietary two-drug combo, when used with Sovaldi, did not produce strong cure rates in short-term therapy, but an eight-week regimen in treatment-naïve cirrhotic patients may offer an advantage over Harvoni. Also, researchers estimate the total cost to treat HCV and recommend need-based prioritization of therapy.
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.